b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">31738425</PMID>\n        <DateCompleted>\n            <Year>2020</Year>\n            <Month>07</Month>\n            <Day>08</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>07</Month>\n            <Day>08</Day>\n        </DateRevised>\n        <Article PubModel="Print">\n            <Journal>\n                <ISSN IssnType="Electronic">1569-8041</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>30</Volume>\n                    <Issue>Suppl_8</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>11</Month>\n                        <Day>01</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title>\n                <ISOAbbreviation>Ann. Oncol.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>viii31-viii35</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdz382</ELocationID>\n            <Abstract>\n                <AbstractText Label="BACKGROUND">The ETV6-NTRK3 gene fusion is present in the majority of cases of infantile fibrosarcoma (IFS) and acts as a potent oncogenic driver. We report the very rapid, complete, and sustained response of an advanced, chemotherapy-refractory, recurrent IFS to targeted treatment with the oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib.</AbstractText>\n                <AbstractText Label="PATIENT AND METHODS">A male infant born with a large congenital IFS of the tongue had the tumour surgically resected at age 4 days. Within 2 months, he developed extensive lymph node recurrence that progressed during two cycles of vincristine-doxorubicin-cyclophosphamide chemotherapy. At screening, a large right cervical mass was clinically visible. Magnetic resonance imaging (MRI) revealed bilateral cervical and axillary lymph node involvement as well as infiltration of the floor of the mouth. The largest lesion measured 5.5\xc3\x974.5\xc3\x974.4\xe2\x80\x89cm (ca. 55 cm3). The patient started outpatient oral larotrectinib at 20\xe2\x80\x89mg/kg twice daily at age 3.5 months.</AbstractText>\n                <AbstractText Label="RESULTS">After 4 days on treatment, the parents noted that the index tumour was visibly smaller and softer. The rapid tumour regression continued over the following weeks. On day 56 of treatment, the first scheduled control MRI showed the target lesion had shrunk to 1.2\xc3\x971.2\xc3\x970.8\xe2\x80\x89cm (ca. 0.6\xe2\x80\x89cm3), corresponding to a complete response according to the Response Evaluation Criteria In Solid Tumors version 1.1. This response was maintained over subsequent follow-up visits, and on day 112 at the second control MRI the target lymph node was completely normal. At last follow-up, the disease remained in complete remission after 16 months on larotrectinib, with negligible toxicity and no safety concerns.</AbstractText>\n                <AbstractText Label="CONCLUSION(S)">Selective TRK inhibition by larotrectinib offers a novel, highly specific and highly effective therapeutic option for IFS carrying the characteristic ETV6-NTRK3 gene fusion. Its use should be considered when surgery is not feasible. (NCT02637687).</AbstractText>\n                <CopyrightInformation>\xc2\xa9 The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Bielack</LastName>\n                    <ForeName>S S</ForeName>\n                    <Initials>SS</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pediatrics 5 (Oncology, Hematology, Immunology), Center for Pediatric, Adolescent and Women\'s Medicine, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pediatric Hematology and Oncology, University Children\'s Hospital Muenster, Muenster, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Cox</LastName>\n                    <ForeName>M C</ForeName>\n                    <Initials>MC</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Loxo Oncology, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Nathrath</LastName>\n                    <ForeName>M</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pediatric Hematology and Oncology, Klinikum Kassel, Kassel.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Apel</LastName>\n                    <ForeName>K</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pediatrics 5 (Oncology, Hematology, Immunology), Center for Pediatric, Adolescent and Women\'s Medicine, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Blattmann</LastName>\n                    <ForeName>C</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pediatrics 5 (Oncology, Hematology, Immunology), Center for Pediatric, Adolescent and Women\'s Medicine, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Holl</LastName>\n                    <ForeName>T</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pediatrics 5 (Oncology, Hematology, Immunology), Center for Pediatric, Adolescent and Women\'s Medicine, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Jenewein</LastName>\n                    <ForeName>R</ForeName>\n                    <Initials>R</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Radiologic Institute, Center for Pediatric, Adolescent and Women\'s Medicine, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Klenk</LastName>\n                    <ForeName>U</ForeName>\n                    <Initials>U</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pediatrics 5 (Oncology, Hematology, Immunology), Center for Pediatric, Adolescent and Women\'s Medicine, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Klothaki</LastName>\n                    <ForeName>P</ForeName>\n                    <Initials>P</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pediatric Hematology and Oncology, Klinikum Kassel, Kassel.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>M\xc3\xbcller-Abt</LastName>\n                    <ForeName>P</ForeName>\n                    <Initials>P</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Radiologic Institute, Center for Pediatric, Adolescent and Women\'s Medicine, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ortega-Lawerenz</LastName>\n                    <ForeName>S</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute for Pediatric Radiology, Klinikum Kassel, Kassel.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Reynolds</LastName>\n                    <ForeName>M</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Loxo Oncology, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Scheer</LastName>\n                    <ForeName>M</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pediatrics 5 (Oncology, Hematology, Immunology), Center for Pediatric, Adolescent and Women\'s Medicine, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Simon-Klingenstein</LastName>\n                    <ForeName>K</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pediatrics 5 (Oncology, Hematology, Immunology), Center for Pediatric, Adolescent and Women\'s Medicine, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Stegmaier</LastName>\n                    <ForeName>S</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pediatrics 5 (Oncology, Hematology, Immunology), Center for Pediatric, Adolescent and Women\'s Medicine, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Tupper</LastName>\n                    <ForeName>R</ForeName>\n                    <Initials>R</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Loxo Oncology, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Vokuhl</LastName>\n                    <ForeName>C</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Pathology - Section Pediatric Pathology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>von Kalle</LastName>\n                    <ForeName>T</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Radiologic Institute, Center for Pediatric, Adolescent and Women\'s Medicine, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <DataBankList CompleteYN="Y">\n                <DataBank>\n                    <DataBankName>ClinicalTrials.gov</DataBankName>\n                    <AccessionNumberList>\n                        <AccessionNumber>NCT02637687</AccessionNumber>\n                    </AccessionNumberList>\n                </DataBank>\n            </DataBankList>\n            <PublicationTypeList>\n                <PublicationType UI="D002363">Case Reports</PublicationType>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Ann Oncol</MedlineTA>\n            <NlmUniqueID>9007735</NlmUniqueID>\n            <ISSNLinking>0923-7534</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C484319">ETV6-NTRK3 fusion protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D015514">Oncogene Proteins, Fusion</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.-</RegistryNumber>\n                <NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.11.28</RegistryNumber>\n                <NameOfSubstance UI="C041311">tropomyosin kinase</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>PF9462I9HX</RegistryNumber>\n                <NameOfSubstance UI="C000609083">larotrectinib</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D005354" MajorTopicYN="N">Fibrosarcoma</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n                <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>\n                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n                <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>\n                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015514" MajorTopicYN="N">Oncogene Proteins, Fusion</DescriptorName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014062" MajorTopicYN="N">Tongue Neoplasms</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n                <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">infantile fibrosarcoma</Keyword>\n            <Keyword MajorTopicYN="Y">larotrectinib</Keyword>\n            <Keyword MajorTopicYN="Y">tropomyosin receptor kinase inhibition</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>19</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>19</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>7</Month>\n                <Day>9</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31738425</ArticleId>\n            <ArticleId IdType="pii">5628160</ArticleId>\n            <ArticleId IdType="doi">10.1093/annonc/mdz382</ArticleId>\n            <ArticleId IdType="pmc">PMC6859811</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Methods Mol Biol. 2018;1727:1-17</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29222769</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Eur J Cancer. 2009 Jan;45(2):228-47</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19097774</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lancet Oncol. 2018 May;19(5):705-714</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29606586</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Br J Cancer. 2018 Sep;119(6):693-696</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">30220707</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Eur J Cancer. 2016 Apr;57:1-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26849118</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nat Genet. 1998 Feb;18(2):184-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">9462753</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Handb Exp Pharmacol. 2014;220:103-19</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24668471</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer. 2018 Nov 1;124(21):4241-4247</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">30204247</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Hematol Oncol. 2018 Jun 7;11(1):78</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29880008</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2018 Feb 22;378(8):731-739</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29466156</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Pediatr Blood Cancer. 2016 Aug;63(8):1468-70</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27093299</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Mol Cancer Ther. 2017 Oct;16(10):2130-2143</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28751539</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>JCO Precis Oncol. 2018;2018:null</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">30637364</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Pediatr Blood Cancer. 2017 Aug;64(8):null</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28097808</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Postepy Biochem. 2018 Oct 25;64(3):231-241</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">30656908</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Drugs. 2019 Feb;79(2):201-206</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">30635837</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Am J Surg Pathol. 2000 Jul;24(7):937-46</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">10895816</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Eur J Cancer. 2009 Jan;45(2):261-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19091550</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2010 Jan 10;28(2):318-23</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19917847</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'